Synopsis Amiodarone, originally developed over 20 years ago, is a potent antiarrhythmic
drug with the actions of all antiarrhythmic drug classes. It has been successfully used in the …

Twenty-three patients with sustained, recurrent, symptomatic ventricular tachycardia were
treated with oral amiodarone. Initial doses were 600-2000 mg/day and maintenance doses …

Objectives. The goal of this study was to evaluate the effect of amiodarone on mortality,
ventricular arrhythmias and clinical complications in high risk postinfarction patients …

Amiodarone has emerged as the leading antiarrhythmic therapy for termination and
prevention of ventricular arrhythmia in different clinical settings because of its proven …

Objective To review the clinical pharmacology, pharmacokinetics, and clinical efficacy and
safety of intravenous amiodarone. Data Identification Articles were identified through a …

Background Oral amiodarone effectively suppresses ventricular arrhythmias; however, full
activity may take days or weeks. In patients with frequent, life-threatening ventricular …

Amiodarone, an iodinated benzofuran derivative with Class I, II, III, and IV antiarrhythmic
properties, is the most commonly used antiarrhythmic drug used to treat supraventricular …

Objectives. To review management and dosing guidelines for amiodarone therapy, and
discuss the drug's adverse event profile. Methods. Review of relevant studies and reports …

Interest in amiodarone has increased because of its remarkable efficacy as an
antiarrhythmic agent. The purpose of this report is to review what is known about the …

BACKGROUND: There have been 13 randomised controlled trials of prophylactic
amiodarone in patients with recent myocardial infarction (MI) or congestive heart failure …